These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 33734140)
21. Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer. Davies M; Duffield E Clin J Oncol Nurs; 2020 Jun; 24(3):277-283. PubMed ID: 32441679 [TBL] [Abstract][Full Text] [Related]
22. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancaster E; Lai M; Peng X; Hughes E; Constantinescu R; Raizer J; Friedman D; Skeen MB; Grisold W; Kimura A; Ohta K; Iizuka T; Guzman M; Graus F; Moss SJ; Balice-Gordon R; Dalmau J Lancet Neurol; 2010 Jan; 9(1):67-76. PubMed ID: 19962348 [TBL] [Abstract][Full Text] [Related]
23. SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). Borghaei H; Redman MW; Kelly K; Waqar SN; Robert F; Kiefer GJ; Stella PJ; Minichiello K; Gandara DR; Herbst RS; Papadimitrakopoulou VA Clin Lung Cancer; 2021 May; 22(3):178-186. PubMed ID: 33358401 [TBL] [Abstract][Full Text] [Related]
24. Durvalumab for the treatment of non-small cell lung cancer. Murakami S Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989 [No Abstract] [Full Text] [Related]
25. Immune Checkpoint Inhibitor-Induced Hypoparathyroidism Associated With Calcium-Sensing Receptor-Activating Autoantibodies. Piranavan P; Li Y; Brown E; Kemp EH; Trivedi N J Clin Endocrinol Metab; 2019 Feb; 104(2):550-556. PubMed ID: 30252069 [TBL] [Abstract][Full Text] [Related]
26. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy. Ragavan M; Das M Curr Treat Options Oncol; 2020 Jun; 21(8):64. PubMed ID: 32601742 [TBL] [Abstract][Full Text] [Related]
27. Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis. Kim TJ; Lee ST; Shin JW; Moon J; Lim JA; Byun JI; Shin YW; Lee KJ; Jung KH; Kim YS; Park KI; Chu K; Lee SK J Neuroimmunol; 2014 May; 270(1-2):45-50. PubMed ID: 24662003 [TBL] [Abstract][Full Text] [Related]
28. Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report. Makiguchi T; Tanaka H; Kamata K; Taima K; Kurose A; Tasaka S Thorac Cancer; 2021 Oct; 12(20):2811-2814. PubMed ID: 34405563 [TBL] [Abstract][Full Text] [Related]
29. Lung Cancer Wherein Durvalumab Induced Both Anti-CRMP-5 Antibody-related Paraneoplastic Neurological Syndromes and Neurological Adverse Events. Seki T; Baba K; Hayashi T; Furuta R; Hirosawa H; Mitsui T; Maesaka H; Takasawa S; Miwa T; Tanaka K; Nakatsuji Y Intern Med; 2024 Apr; 63(7):1009-1014. PubMed ID: 37612090 [TBL] [Abstract][Full Text] [Related]
30. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. Berner F; Bomze D; Diem S; Ali OH; Fässler M; Ring S; Niederer R; Ackermann CJ; Baumgaertner P; Pikor N; Cruz CG; van de Veen W; Akdis M; Nikolaev S; Läubli H; Zippelius A; Hartmann F; Cheng HW; Hönger G; Recher M; Goldman J; Cozzio A; Früh M; Neefjes J; Driessen C; Ludewig B; Hegazy AN; Jochum W; Speiser DE; Flatz L JAMA Oncol; 2019 Jul; 5(7):1043-1047. PubMed ID: 31021392 [TBL] [Abstract][Full Text] [Related]
31. Rituximab for nivolumab plus ipilimumab-induced encephalitis in a small-cell lung cancer patient. Ito M; Fujiwara S; Fujimoto D; Mori R; Yoshimura H; Hata A; Kohara N; Tomii K Ann Oncol; 2017 Sep; 28(9):2318-2319. PubMed ID: 28911080 [No Abstract] [Full Text] [Related]
32. Bullous Pemphigoid Associated With a New Combination Checkpoint Inhibitor Immunotherapy. Fontecilla NM; Khanna T; Bayan CY; Antonov NA; Geskin LJ J Drugs Dermatol; 2019 Jan; 18(1):103-104. PubMed ID: 30681807 [TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System. Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349 [TBL] [Abstract][Full Text] [Related]
37. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. Williams TJ; Benavides DR; Patrice KA; Dalmau JO; de Ávila AL; Le DT; Lipson EJ; Probasco JC; Mowry EM JAMA Neurol; 2016 Aug; 73(8):928-33. PubMed ID: 27271951 [TBL] [Abstract][Full Text] [Related]
38. GABA-B Receptor Encephalitis Triggered by Enterovirus Encephalitis in a Patient With Small Cell Lung Cancer: A Case Report. Kim SH; Kim W Neurologist; 2020 Jul; 25(4):106-108. PubMed ID: 32618841 [TBL] [Abstract][Full Text] [Related]
39. Durvalumab-induced lesions of bronchiolitis and fully reversible bronchiectasis in a patient with non-small cell lung cancer: A case report. Domblides M; Geier M; Decroisette C; Descourt R Thorac Cancer; 2021 Apr; 12(8):1240-1243. PubMed ID: 33624409 [TBL] [Abstract][Full Text] [Related]
40. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Barlesi F; Vansteenkiste J; Spigel D; Ishii H; Garassino M; de Marinis F; Özgüroğlu M; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Ellers-Lenz B; Bajars M; Ruisi M; Park K Lancet Oncol; 2018 Nov; 19(11):1468-1479. PubMed ID: 30262187 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]